Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 71

Results For "2023"

1167 News Found

USFDA completes PAD E inspection of Marksans' Goa facility
Drug Approval | August 09, 2023

USFDA completes PAD E inspection of Marksans' Goa facility

The inspection was conducted at its Goa, Vema manufacturing facility


KIMS posts Q1 FY24 consolidated PAT at Rs. 80.81 Cr
News | August 08, 2023

KIMS posts Q1 FY24 consolidated PAT at Rs. 80.81 Cr

KIMS has reported total income of Rs. 609.14 crores during the period ended June 30, 2023


Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr
News | August 08, 2023

Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023


Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr
News | August 08, 2023

Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr

Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023


Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
News | August 06, 2023

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023


Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
Drug Approval | August 06, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023


Fortis Healthcare Q1 FY24 consolidated PAT drops at Rs. 111.76 Cr
News | August 06, 2023

Fortis Healthcare Q1 FY24 consolidated PAT drops at Rs. 111.76 Cr

Fortis Healthcare has reported total income of Rs. 1665.55 crores during the period ended June 30, 2023


Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr
News | August 06, 2023

Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr

The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023


Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma
Drug Approval | August 06, 2023

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated